PUBLIC COMPANY
save$MRNAModerna, Inc.
$MRNA214.16+2.98%Cambridge, MA, USupdated 23d ago
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
community read0 votes
pipeline
18
marketed
5
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(18)
view full pipeline →pipeline depth18 products
5Phase 15Phase 21Phase 35Marketed2pre_registration
Marketed
Coronavirus Disease 2019 (COVID-19) KP.2 vaccine
Coronavirus Disease 2019 (COVID-19)
MarketedCoronavirus Disease 2019 (SARS-CoV-2) vaccine 2
Coronavirus Disease 2019 (COVID-19)
Marketeddavesomeran + elasomeran
Coronavirus Disease 2019 (COVID-19)
Marketedelasomeran
Coronavirus Disease 2019 (COVID-19)
MarketedmNEXSPIKE
Coronavirus Disease 2019 (COVID-19)
Phase 3mRNA-1403
Norovirus Infections
Phase 2intismeran autogene
Metastatic Melanoma
Phase 2mRNA-3705
Methylmalonic Acidemia
Phase 2mRNA-3927
Propionic Acidemia
Phase 2mRNA-4359
Solid Tumor
Phase 2respiratory syncytial virus vaccine
Respiratory Syncytial Virus (RSV) Infections
Fusion glycoprotein F0
Phase 1mRNA-1215
Nipah Virus (NiV) Infections
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Wall Street consensus
source: yahoo finance · 20 analystsmean target
$46.10
vs $49.56 now
implied upside
-7.0%
range: $21.00 – $135.00
consensus rating
Hold
2.96 / 5.0
rating distribution · 23 analysts
1
2
17
1
2
strong buystrong sell
🐶 Hiring Signal
Where Moderna, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
News
- As part of sales reorganization, Novo will cut 215 employees at US HQFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 14h ago
- FDA’s search for a new leader, and China’s largest drugmakersThis week on "The Readout LOUD" podcast: the FDA is again searching for a new leader and a closely tracked lung cancer drug suffers an agency rejection.stat · 20h ago
- Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concernsMerck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.biospace · 2d ago
- Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s StarnaPfizer has decided to join the in vivo CAR-T race, penning a $2.6 billion deal for three preclinical candidates from China’s Starna Therapeutics.fiercebiotech · 2d ago
- Scientists uncover ‘very detailed map’ of an enzyme target for rare metabolic diseaseFor some rare genetic diseases, the problem isn't a missing protein but the buildup of toxic molecules that the body can no longer clear away.fiercebiotech · 3d ago
- The future of heart drug research in the wake of study setbacksWhat does the failure of two closely watched heart disease medicines mean for the future of drug research in the field? Find out on this week's episode of "The Readout…stat · 7d ago
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 11d ago
- Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think soFor executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…fiercebiotech · 13d ago
- Democrats’ midterm victory, and a questionable fertility procedureHow will the midterm results affect drug pricing policy? And why are women traveling to fertility clinics abroad? Find out on the new episode of "The Readout LOUD" podcast.stat · 14d ago
- Moderna enjoys stable vaccine sales thanks to global COVID uptakeWhile Moderna preps an entry to the oncology market next year with a personalized cancer vaccine, COVID sales are holding steady with several other vaccine launches underway around the world.biospace · 14d ago
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that